Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models

This publication has 27 references indexed in Scilit:

• Suppressing Orthotopic Pancreatic Tumor Growth with a Fiber-Modified Adenovector Expressing the TRAIL Gene from the Human Telomerase Reverse Transcriptase Promoter
  Clinical Cancer Research, 2004
• Overcoming Acquired Resistance to TRAIL by Chemotherapeutic Agents and Calpain Inhibitor I through Distinct Mechanisms
  Molecular Therapy, 2004
• A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver Metastases
  Molecular Therapy, 2004
• Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL
  Cancer Gene Therapy, 2004
• E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
  Nature Biotechnology, 2003
• Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway
  JNCI Journal of the National Cancer Institute, 2003
• Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells
  Oncogene, 2002
• Cooperation of E2F-p130 and Sp1-pRb Complexes in Repression of the Chinese Hamster dhfr Gene
  Molecular and Cellular Biology, 2001
• Cdk2-dependent Phosphorylation and Functional Inactivation of the pRB-related p130 Protein in pRB(−), p16INK4A(+) Tumor Cells
  Published by Elsevier ,2000
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
  Oncogene, 2000